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Abstract
Purpose—Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are
medications widely prescribed to reduce cholesterol levels. Observational studies in high-risk
populations, mostly in Asia, have suggested that statins are associated with a reduced risk of
hepatocellular carcinoma (HCC). The current study sought to evaluate the association of statin use
and HCC in a U.S.-based, low-risk, general population.
Methods—A nested case-control study was conducted among members of the Health Alliance
Plan HMO of the Henry Ford Health System enrolled between 1999 and 2010. Electronic
pharmacy records of statin use were compared among tumor registry-confirmed cases of HCC
(n=94) and controls (n=468) matched on age, sex, diagnosis date, and length of HMO enrollment.
Results—In multivariate analyses, ever-use of statins was significantly inversely associated with
development of HCC (Odds Ratio (OR):0.32, 95%CI: 0.15–0.67). No clear dose-response
relationship was evident as statin use for ≤2 years (OR=0.32, 95%CI=0.13–0.83) and >2 years
(OR=0.31, 95CI%=0.12–9.81) resulted in very similar ORs.
Conclusions—The use of statins among populations in low-risk HCC areas may be associated
with decreased risk of HCC.
Keywords
statins; liver cancer; epidemiology
Correspondence to: Katherine A. McGlynn, Ph.D., Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH,
DHHS, 6120 Executive Boulevard, EPS-Suite 550, Rockville, MD 20852-7234.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of interest: None to declare
NIH Public Access
Author Manuscript
Cancer Epidemiol. Author manuscript; available in PMC 2015 October 01.
Published in final edited form as:























Primary liver cancer, of which hepatocellular carcinoma (HCC) is the dominant histologic
type, is the sixth most commonly occurring cancer in the world and due to a very poor
prognosis, the second most frequent cause of cancer mortality (1). In the majority of high
risk HCC areas, the most common risk factors are hepatitis B virus (HBV) infection and
aflatoxin contamination of foodstuffs (2). In contrast, in low risk areas, the most common
risk factors are excessive alcohol consumption, hepatitis C virus (HCV) infection and
diabetes (2). Incidence rates of HCC have begun to decline in some high risk regions, but
have been increasing in many low rate regions (2). The declining rates in high risk areas
may be related to public health efforts and HBV vaccination, while the rising rates in low
risk areas are likely due to the increased prevalence of diabetes, obesity and chronic
infection with HCV (3, 4). Unfortunately, HBV vaccination is of no benefit to persons who
are already chronically infected with the virus and there is no HCV vaccine. As a result, it is
important to examine other means of trying to decrease risk of HCC.
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-Co-A) inhibitors) are
commonly used cholesterol lowering medications which have demonstrated effectiveness in
the primary and secondary prevention of cardiovascular disease (5). Statins also have
antiangiogenic and anti-proliferative properties which have suggested a possible role for
their use as anti-carcinogenic agents (6–8). A potential for HCC prevention is further
indicated as statins, post-administration, are localized to the liver (9). Promising evidence
that statins may decrease risk of HCC has been reported in observational studies from
Taiwan, a high-risk HCC area (10–14). Two U.S. studies also reported an inverse
association between statins and HCC (15, 16), although the population of one of the studies
was confined to men with diabetes (15). In contrast, null associations between statins and
HCC have been reported by two cohort studies in low-risk areas (17, 18) and by secondary
analyses of randomized clinical trials of cardiovascular disease prevention (19–21). Recent
meta-analyses (22, 23) have concluded that statins are associated with reduced risk of HCC,
although one meta-analysis felt that the effect might be confined to Asian populations (23).
Given the ambiguous results to date from low-risk populations, the current study sought to
evaluate the risk of HCC among members of a health maintenance organization (HMO) in a
low-incidence region (United States).
Materials and Methods
A nested case-control study was conducted among the population of the Health Alliance
Plan HMO of the Henry Ford Health System (HFHS), a single integrated health system. The
study encompassed the years between 1999 and 2010. Complete, population-based case
ascertainment was conducted using an internal cancer registry, which is part of the National
Cancer Institute’s Detroit Surveillance, Epidemiology and End Results (SEER) registry. In
the registry, all potential cancer cases are investigated and, if determined to be a new
primary case, are examined in detail. Cancer registry data include basic demographic
information (e.g., birthdates, age, sex, race/ethnicity), histopathologic characteristics, stage,
and vital status. Use of computerized pharmacy records allowed examination of several
measures of statin use, including overall exposure (ever vs. never) and cumulative exposure
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(sum of days’ supply for all statin prescriptions). All members of the HMO purchase
prescription medications at minimal cost. All study variables were obtained from the
automated data systems within the HFHS. There was no direct contact with HMO members.
The protocol was approved by the HFHS Institutional Review Board and the Human
Research Protections Program of the NIH.
Persons selected as cases were identified using ICD-O-3 topography code C22 and
morphology codes 8170–8175 (24). Persons selected as cases or controls had to be enrolled
in the HMO for at least two years prior to diagnosis date or index date (for controls). Once
cases were identified through the tumor registry, controls were selected from the same
population that gave rise to the cases. Using incidence density matching, controls were
matched to cases at a ratio of 5:1 on age (two year strata), length of HMO enrollment (two
year strata), diagnosis date, and sex. Controls could have no prior history of HCC up to the
diagnosis date of the matched case.
Statistical analysis was initiated by conducting univariate analyses of association using chi-
square tests or exact tests for variables with small numbers in any cell. Odds ratios (OR) and
their 95% confidence intervals (95%CI) were calculated as estimates of the relative risk for
HCC associated with statin use, using conditional logistic regression. Exposure to statins
was defined in several different ways. First, assessment of ever having a statin prescription
filled was analyzed. A second analysis assessed the cumulative exposure to statins.
Cumulative exposure was defined as the sum of days’ supply for all prescriptions filled prior
to diagnosis or index date. A categorical analysis was conducted which dichotomized
cumulative exposure based on the median exposure among the cases who were exposed.
Finally, an analysis of medication possession ratio was conducted where medication
possession ratio was defined as cumulative years’ supply of statins divided by the length of
HMO enrollment prior to diagnosis/index date. The categorical analysis dichotomized the
medication possession ratio on the median among the cases who were exposed. Both
univariate and multivariate analyses were conducted for each exposure definition.
Multivariate analyses adjusted for pre-existing medical conditions and known risk factors
for HCC that were significantly related to case/control status in the univariate analysis.
Conditions examined included type 2 diabetes, hepatitis B virus (HBV) infection, hepatitis C
virus (HCV) infection, hypertension, alcohol-related conditions (alcoholic fatty liver, acute
alcoholic hepatitis, alcoholic cirrhosis of liver, cirrhosis of the liver without mention of
alcohol in combination with alcohol-induced mental disorders or alcohol dependence
syndrome or nondependent abuse of drugs) and chronic obstructive pulmonary disease
(COPD). COPD was included as a proxy variable for heavy cigarette smoking. The medical
conditions were identified in the electronic medical records by use of ICD-9 codes
(Supplemental Table). In addition to the main analyses, a sensitivity analysis examined the
statins-liver cancer relationship after eliminating any exposed user who had taken statins
less than 6 months.
Results
Overall, 94 cases of HCC were identified and matched to 468 controls. Table 1 displays the
distribution of characteristics in the study participants by case-control status. Cases were
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more likely than controls to have alcohol-related conditions, diabetes, chronic obstructive
pulmonary disease and hypertension and to be positive for HCV. Cases were also more
likely than controls to be of known racial designation. There were no differences between
cases and controls in HBV positivity. There were also no differences, as expected, in the
distributions of the matching factors: sex, age at index date, diagnosis date and length of
HMO enrollment. While at least 2 years of HMO enrollment prior to diagnosis or index date
was required, the average length of enrollment was 8.1 years (SD ± 3.8) with a range of 2
years to 15 years.
Table 2 displays the results of the univariate and multivariate conditional logistic regression
analyses. In both the univariate (OR=0.34, 95%CI=0.21–0.57) and multivariate (OR: 0.32,
95%CI: 0.15–0.67) analyses, ever use of statins was significantly inversely related to HCC.
An analysis of the cumulative supply of statins found that, compared with non-use, there
was a significantly decreased risk of HCC with use of <2 years (OR=0.32, 95%CI=0.13–
0.83) and use of >2 years (OR=0.31, 95%CI=0.12–0.81). Similarly, compared to non-use,
there was a significantly decreased statins possession ratio (supply of statins/length of HMO
enrollment) with both lower use (OR: 0.26, 95%CI: 0.10–0.70) and greater use (OR=0.38,
95%CI=0.15–0.93).
The sensitivity analysis which dropped exposed person who had taken statins less than 6
months resulted in a finding very similar to the main result (OR=0.26, 95%CI=0.11–0.66).
Discussion and Conclusions
In the current study, statin use was significantly inversely associated with HCC. These
findings suggest that statin use may protect against the development of HCC in populations
living in low-risk HCC areas.
Much of the prior evidence on statins and HCC has been drawn from studies that utilized the
Taiwan National Health Insurance Research Database (10–14). In a case-control analysis of
1,166 liver cancer cases and 1,166 controls in the database, Chiu et al (10) reported a
significant inverse association between statin use and HCC (OR=0.53, 95%CI=0.45–0.83),
which was replicated by Leung et al. (OR=0.44, 95%CI=0.28–0.72) (12). Using the same
database, Tsan et al reported significant inverse associations of statins and HCC among
persons infected with HBV (OR=0.47, 95%CI=0.36–0.61) (14) and persons infected with
HCV (OR=0.53, 95%CI=0.49–0.58) (13). Lai et al. (11), also using the database, reported
that the inverse association between statin use and HCC was statistically significant for use
of simvastatin (OR=0.69, 95%CI=0.50–0.94), lovastatin (OR=0.52, 95%CI=0.36–0.76) and
atorvastatin (OR=0.70, 95%=0.53–0.93), but not for use of fluvastatin, pravastatin or
rosuvastatin, although the odds ratios for the latter three statins were less than one.
The effect of statins on liver cancer or HCC risk has also been examined in several studies
conducted in low-risk liver cancer countries. In a prospective study from Denmark, Friis et
al found no support (OR=1.16, 95%CI=0.46–2.90) for an association between statin use and
liver cancer (17). Conversely, support was found in two U.S. studies of HCC conducted
among the U.S. Department of Veterans Affairs’ patient population. Both El-Serag et al.
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(15), studying men with diabetes (OR=0.74, 95%CI=0.64–0.87), and Khurana et al. (25),
studying men with HCV infection (OR=0.52, 95%CI=0.41–0.67) reported significantly
reduced risks. In an analysis of the General Electric Centricity electronic medical records
database of the U.S., Marelli and colleagues (18) reported that there was no significant
association between statin use and liver cancer although they did find that liver cancer
occurred among 0.37% of non-statin users, but only among 0.10% of statin users. Why the
results of Friis et al. (17) and Marelli et al. (18) differ from those of El-Serag et al. (15) and
Khurana et al. (25) is not certain, although the specificity of the study outcomes differ in that
the Veterans Affairs’ studies examined HCC, while the other two studies included all
primary liver cancers. Two meta-analyses that have specifically examined statins and liver
cancer/HCC both concluded that statin use was associated with a reduced risk (22, 23).
In addition to observational studies, secondary analyses of cardiovascular disease
randomized controlled trials have attempted to examine the risk of cancer in relation to
statins. The great majority of secondary analyses, however, have not included information
on liver cancer. Of the trials that have reported on liver cancer, none have found a
statistically significant association. Sato et al. (21) reported an observed/expected ratio of
0.63 (95%CI=0.01–3.49) in a pravastatin trial that included 179 participants in the statins
arm, one of whom developed liver cancer. Matsushita et al. (20), in a meta-analysis of three
Japanese studies of pravastatin, reported a hazard ratio of 0.58 (0.18–1.84) based on 7 liver
cancers in the control group and 5 liver cancers in the pravastatin group. Similarly, in a large
meta-analysis of cancer outcomes in 27 trials (19), no relationship between statin use and
liver cancer was identified (p=0.39), with 42 liver cancers reported in the statins arm and 51
in the control arm. None of the RCTs have reported on HCC as an outcome. Overall, the
information from the secondary analysis of cardiovascular disease trials is limited by the fact
that liver cancer is a rare outcome, and HCC even rarer, and it is an outcome that takes years
to develop.
One concern raised about the statins-liver cancer findings is that they could result from
persons with liver disease not being as likely to receive statin therapy as persons without
liver disease. Statins have been associated with elevated aminotransferase levels in fewer
than 5% of persons (26), but questions about liver damage may have led to reluctance to
prescribe them to persons with liver disease. As the majority of individuals who develop
liver cancer have pre-existing liver disease, the failure to prescribe statins for these
individuals could result in what appears to be a protective association. Several studies have
attempted to address this concern by doing stratified analyses of their data. In a stratified
analysis that only included persons without liver disease, El-Serag et al. (15) found that
statins remained significantly inversely related to liver cancer. Similarly, Chiu et al. (10)
stratified participants into those with and without cirrhosis and found a dose-dependent
reduction in risk among both groups. No stratification on liver disease status was possible in
the current study given the sample size. Further analysis in future studies, however, may
help to clarify this issue. In addition, recent reports suggest that concerns about prescribing
statins to persons with liver disease may have been overstated (27, 28).
The mechanism by which statins might prevent HCC is not certain, but may be related to the
inhibition of HMG-CoA reductase in the mevalonate pathway which could decrease the
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likelihood of tumor initiation and progression (29). Statins may also exert effects
downstream of the mevalonate pathway by disrupting the growth of transformed cells and
stimulating apoptosis (6). In persons infected with HCV, statins have also been
demonstrated to inhibit viral replication via depletion of mevalonate which leads to low
levels of geranylgeranyl phosphate which is needed for HCV replication (30). In persons
infected with HBV, a possible mechanism of action is simply the lowering of cholesterol
levels as cholesterol depletion impairs the ability of HBV to infect target cells (31).
Strengths of the current study are that it examined HCC risk in a general population setting
and that statin exposure was documented via use of pharmacy prescription records. In
addition, all study participants were able to obtain their medications at minimal cost. The
study was able to adjust for major known HCC risk factors such as alcohol-related
conditions, HCV, HBV and diabetes. Limitations of the study are its relatively small size
and lack of information on lifestyle exposures such as alcohol consumption and cigarette
smoking. Proxy medical conditions for these exposures, however, were examined. In
addition, concomitant use of other possible chemopreventive medications, such as
metformin (32) and non-steroidal anti-inflammatory drugs (33), was not included in the
analysis.
In conclusion, the majority of the evidence, including that in the current study, suggests that
statins may reduce the risk of HCC. Further studies of this question, however, are warranted
to examine dose-response relationships and to be certain that the association is not due to
failure to prescribe statins to persons with liver disease. In addition, the benefits of use of
any pharmaceutical agent, particularly as a chemopreventive agent, should be carefully
balanced against the possible risks of adverse effects. However, it is possible that if these
results hold up in other studies, statins may offer an opportunity to intervene in the rising
incidence of HCC now seen in many populations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• The inclusion of the larger dataset is explicitly detailed to the Reveiwers.
• The analyses were dichotomized on the medians of cumulative exposure among
the statins-exposed individuals.
• The use of exact test and their p-values has been added to the Material and
Methods section.
• The results of the sensitivity analysis which persons on statins for <6 months are
reported.
• The results remain consistent with a significant inverse association between
statin use and HCC.
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